Methscopolamine

Summary

Methscopolamine (CHEMBL376897) is an approved small molecule (ATC A03BB03); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A03BB03 (+1 more)
• Indications: 1 condition
• Chemistry: 318.4 Da · C18H24NO4+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL376897
Name	Methscopolamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	71183
ATC	A03BB03, S01FA03
Molecular formula	C18H24NO4+
Molecular weight	318.4
InChIKey	LZCOQTDXKCNBEE-XJMZPCNVSA-N

SMILES: C[N+]1([C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4)C

IUPAC name: [(1S,2S,4R,5R)-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoate

Also known as: (-)-n-methylscopolamine, Methscopolamine cation, Methscopolamine ion, Methylscopolamine, N-methylhyoscine, N-methylscopolamine, N-Methylscopolamine, Methyl scopolamine, SID11111827, METHSCOPOLAMINE, N-methyl scopolamine, [3H]-N-methyl scopolamine

Parent form; salt/anhydrous children: CHEMBL1354199, CHEMBL1506225

Patent coverage: 693 distinct patent families (2,568 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Muscarinic acetylcholine receptor M4, Thyrotropin receptor, Muscarinic acetylcholine receptor M5, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M3, Cytochrome P450 2C9, Cytochrome P450 3A4.

Bioactivity

ChEMBL activities: 44 potent at pChembl ≥ 5 of 48 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P08483	10.3	EC50	0.05	nM	CHEMBL_ACT_2185079
CHRM2	10.2	Ki	0.06	nM	CHEMBL_ACT_18236896
CHRM1	10.02	Ki	0.1	nM	CHEMBL_ACT_12180365
CHRM3	9.87	Ki	0.13	nM	CHEMBL_ACT_10927295
CHRM3	9.87	Ki	0.13	nM	CHEMBL_ACT_1821641
CHRM3	9.87	Ki	0.13	nM	CHEMBL_ACT_2983692
CHRM4	9.85	Ki	0.14	nM	CHEMBL_ACT_10927280
CHRM4	9.85	Ki	0.14	nM	CHEMBL_ACT_1821653
CHRM4	9.85	Ki	0.14	nM	CHEMBL_ACT_2983709
CHRM1	9.77	Ki	0.17	nM	CHEMBL_ACT_12180347
CHRM2	9.75	Ki	0.18	nM	CHEMBL_ACT_10927310
CHRM2	9.75	Ki	0.18	nM	CHEMBL_ACT_1821629
CHRM2	9.75	Ki	0.18	nM	CHEMBL_ACT_2983030
P08483	9.71	EC50	0.2	nM	CHEMBL_ACT_2185080
CHRM5	9.68	Ki	0.21	nM	CHEMBL_ACT_10927265
CHRM5	9.68	Ki	0.21	nM	CHEMBL_ACT_1821665
CHRM5	9.68	Ki	0.21	nM	CHEMBL_ACT_2983726
CHRM1	9.49	Ki	0.32	nM	CHEMBL_ACT_10927325
CHRM1	9.49	Ki	0.32	nM	CHEMBL_ACT_1821617
CHRM1	9.49	Ki	0.32	nM	CHEMBL_ACT_2983013
CHRM2	9.48	Ki	0.33	nM	CHEMBL_ACT_15059758
CHRM2	9.37	Ki	0.43	nM	CHEMBL_ACT_15056232
CHRM2	9.36	Ki	0.44	nM	CHEMBL_ACT_15059773
CHRM2	9.33	Kd	0.47	nM	CHEMBL_ACT_1821689
CHRM2	9.14	Ki	0.72	nM	CHEMBL_ACT_15059743
CHRM3	8.96	IC50	1.1	nM	CHEMBL_ACT_76493
CHRM5	8.95	Ki	1.12	nM	CHEMBL_ACT_15059788
CHRM2	8.92	Ki	1.2	nM	CHEMBL_ACT_18236886
CHRM1	8.74	IC50	1.8	nM	CHEMBL_ACT_76491
CHRM4	8.64	IC50	2.3	nM	CHEMBL_ACT_76494

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).